Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Por Ramos, Nestor R., Mo, Clifton C., Karp, Judith E., Hourigan, Christopher S.
Publicado no J Clin Med (2015)

Multigene measurable residual disease assessment improves AML relapse risk stratification in autologous hematopoietic cell transplantation

Por Mulé, Matthew P., Mannis, Gabriel N., Wood, Brent L., Radich, Jerald P., Hwang, Jimmy, Ramos, Nestor R., Andreadis, Charalambos, Damon, Lloyd, Logan, Aaron C., Martin, Thomas G., Hourigan, Christopher S.
Publicado no Biol Blood Marrow Transplant (2016)

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response

Por Wong, Hong Yuen, Sung, Anthony D., Lindblad, Katherine E., Sheela, Sheenu, Roloff, Gregory W., Rizzieri, David, Goswami, Meghali, Mulé, Matthew P., Ramos, Nestor R., Tang, Jingrong, Thompson, Julie, DeStefano, Christin B., Romero, Kristi, Dillon, Laura W., Kim, Dong-Yun, Lai, Catherine, Hourigan, Christopher S.
Publicado no Front Oncol (2019)